We are live on ! Find out more
ACET icon

Adicet Bio
ACET

64 hedge funds and large institutions have $82.3M invested in Adicet Bio in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $77.4M → $82.3M (+$4.83M)

0.53% less ownership

Funds ownership: 4.87% → 4.33% (-0.53%)

26% less funds holding

Funds holding: 86 → 64 (-22)

30% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 23

67% less call options, than puts

Call options by funds: $6K | Put options by funds: $18K

76% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 29

Holders
64
Holders Change
-22
Holders Change %
-25.58%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
16
Reduced
23
Closed
29
Calls
$6K
Puts
$18K
Net Calls
-$12K
Net Calls Change
+$25K

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.11M
2
BCM
Bridgeway Capital Management
Texas
+$924K
3
RC
RBF Capital
California
+$323K
4
Marshall Wace
Marshall Wace
United Kingdom
+$154K
5
DC
Diametric Capital
Massachusetts
+$154K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.33M
2
RI
RTW Investments
New York
-$1.27M
3
Morgan Stanley
Morgan Stanley
New York
-$1.19M
4
CAC
Cowen and Company
New York
-$970K
5
OCA
Octagon Capital Advisors
New York
-$929K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$16.5M – – –
TCM
2
Tang Capital Management
California
$11.8M – – –
RCM
3
RA Capital Management
Massachusetts
$10.9M – – –
Goldman Sachs
4
Goldman Sachs
New York
$5.41M -$732K -32,711 -12%
Vanguard Group
5
Vanguard Group
Pennsylvania
$4.62M +$148K +6,621 +3%
CG
6
Carlyle Group
District of Columbia
$4.25M – – –
ACM
7
Aquilo Capital Management
California
$3.64M – – –
Millennium Management
8
Millennium Management
New York
$2.82M -$2.33M -103,934 -46%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$2.71M +$1.11M +49,678 +73%
Blackstone Inc
10
Blackstone Inc
New York
$1.78M – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$1.77M -$393K -17,563 -19%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$1.32M +$113K +5,065 +10%
BCM
13
Bridgeway Capital Management
Texas
$1.23M +$924K +41,269 +345%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.11M +$137K +6,098 +15%
BlackRock
15
BlackRock
New York
$1.08M -$371K -16,590 -26%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$1.02M +$142K +6,344 +17%
Two Sigma Investments
17
Two Sigma Investments
New York
$1.01M +$101K +4,521 +11%
Alyeska Investment Group
18
Alyeska Investment Group
Illinois
$944K – – –
SCM
19
Stonepine Capital Management
Oregon
$878K – – –
RC
20
RBF Capital
California
$866K +$323K +14,446 +62%
DCM
21
DAFNA Capital Management
California
$864K – – –
Norges Bank
22
Norges Bank
Norway
$619K – – –
JJ
23
Johnson & Johnson
New Jersey
$525K – – –
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$525K +$143K +6,402 +39%
XT
25
XTX Topco
Cayman Islands
$421K +$45.3K +2,024 +12%
1
2 3 4

ACET Hedge Fund Activity: Q3 2024 in Review

64 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q3 2024, worth a combined $82.3M — up 6.2% from $77.4M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ACET and 7 opened new positions — a net loss of 22 holders — while 23 trimmed existing stakes and 16 added.

The largest buyer was Acadian Asset Management, adding an estimated $1.11M. The largest seller was Millennium Management, cutting an estimated $2.33M.

  • 64 institutional investors held Adicet Bio (ACET) as of Q3 2024, down from 86 in Q2 2024.
  • Funds reported $82.3M of Adicet Bio stock for Q3 2024, up 6.2% quarter-over-quarter.
  • 7 funds opened new Adicet Bio positions in Q3 2024 and 29 closed out, a net change of -22 holders.
  • The largest Adicet Bio buyer in Q3 2024 was Acadian Asset Management, an estimated $1.11M added.
  • The largest Adicet Bio seller in Q3 2024 was Millennium Management, an estimated $2.33M sold.

Based on aggregated 13F filings for Q3 2024.